What Caused The Predictive Oncology (POAI) Stock To Rise In After-Hours Session?

0
111

Shares of Predictive Oncology Inc. (POAI) were up 12.39% at $0.2894 at the time of the most recent check in after-hours trading due to the company’s announcement of multiple executive-level appointments.

Who has been chosen by POAI?

David S. Smith, J.D., has been added to the board of directors of Predictive Oncology (POAI), the firm said on Tuesday.


Do You Own These 7 Inflation-Survival Stocks?

Inflation is still near 40-year highs and rising prices are putting a big dent in our wallets. Unless you find out how to protect your portfolio and outpace inflation, you'll keep being at the mercy of economic factors out of your control. Especially since the price of electricity, food, and shelter are creeping up higher than ever. In this special report, I detail 7 stocks to help you survive and thrive in today's market. They're backed by solid companies, positioned to profit during tough economic times, and offer out-sized dividends to help you outpace inflation.

Click here to get your free copy of the report

Sponsored


  • Smith is a renowned expert on the legal concerns relating to the therapeutic use of human tissue and cells.
  • He is a life science and business lawyer, a seasoned executive in the biotech sector. He has a wealth of expertise in business transactions, venture financings, and regulatory issues for investors and life sciences enterprises.
  • David Smith is a legal expert and a significant thought leader in the field of life sciences, particularly with regard to intellectual property and the use of human tissue for research and commerce.
  • He has an unmatched awareness of the importance and value of our private biorepository, particularly in relation to the biopharmaceutical sector.
  • Smith has written extensively on subjects including human tissue treatments and tissue engineering research.
  • He regularly lectures on issues pertaining to the commercial development of tissue, cell, and stem cell technology.
  • His nomination to the board coincides with the projected expansion of POAI’s flagship technology, which combines artificial intelligence with the biggest commercial archive of tissue samples in the world to aid in the discovery of new cancer drugs.

New POAI CEO:

Raymond F. Vennare has been appointed as chief executive officer and chairman of the board of Predictive Oncology (NASDAQ: POAI), effective as of November 1. As an accomplished senior executive with more than three decades of experience developing biotechnology and bioinformatics companies across diverse markets in the life sciences, Mr. Vennare emerged as a clear frontrunner to serve as the next Chief Executive Officer of Predictive Oncology. He has been an active member of the POAI Board of Directors since September 2021.

How will the next CEO lead?

Mr. Vennare will continue to collaborate closely with senior management at Predictive Oncolgy (POAI) to increase the company’s portfolio of patented solutions and progress the pipeline for oncology drug development, from early discovery through clinical trials. He will oversee POAI’s efforts to advance the company’s core goods and services, including its leading technology that applies 3D tumor models and formulation options to the world’s biggest commercial biobank for the discovery of cancer drugs.

LEAVE A REPLY

Please enter your comment!
Please enter your name here